729 results about "High glucose" patented technology

A health-monitoring device assesses the health of a user based on levels of two analytes in a biological fluid. A first analyte that is utilized to assess a user's health is a fat metabolism analyte, such as ketones, free fatty acids and glycerol, which is indicative of fat metabolism. A second analyte that is utilized is a glucose metabolism analyte, such as glucose. The levels of the two analytes may be used to assess insulin sensitivity, to detect both recent hypoglycemia and the cause of high glucose levels, and/or to guide therapeutic intervention. The dual analyte model may calculate a discrepancy between an actual insulin activity level and a theoretical insulin activity level. The dual analyte model of the present invention may be used to identify individuals at risk for metabolic syndrome, insulin resistance and non-insulin dependent diabetes, and allows monitoring of the progression of those disease states, as well as progress made by therapeutic interventions.

A system and method provides a glucose report for determining glycemic risk based on an ambulatory glucose profile of glucose data over a time period, a glucose control assessment based on median and variability of glucose, and indicators of high glucose variability. Time of day periods are shown at which glucose levels can be seen. A median glucose goal and a low glucose line provide coupled with glucose variability provide a view into effects that raising or lowering the median goal would have. Likelihood of low glucose, median glucose compared to goal, and variability of glucose below median provide probabilities based on glucose data. Patterns can be seen and provide guidance for treatment.

The invention relates to a method for minimizing mean blood glucose levels in an insulin dependent patient by administering insulin to the patient in a sufficiently fast manner to provide a difference of 50% or less between high and low blood glucose levels. Advantageously, the insulin is administered to the patient by jet injection and the high and low blood glucose levels differ by an amount that is less than that which would be obtained after injection of insulin by a conventional needle syringe. The invention also relates to a method for reducing mean blood glucose levels in an insulin dependent patient that is receiving insulin through a conventional syringe and needle arrangement. This method provides for administration of the insulin to the patient by jet injection rather than by the syringe by substituting a jet injector for the syringe.

The invention relates to the technical field of microorganism, and discloses a Lactobacillus reuteri and its application. The preservation number of the Lactobacillus reuteri CCFM8631 is CGMCC No.14394; the level of mice peripheral neurotransmitter 5-hydroxytryptamine can be significantlyimproved; the rise of the mice peripheral blood testonsterone level and the abundant abnormity of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora by high glucose and high fatty diets are recovered; the tolerated simulative gastrointestinal fluid is rapidly planted in an intestinal tract, so as to significantly improve the pathological injury of metabolic syndrome mice liver and duodenum and rise of triglyceride and total cholesterol content in the serum by high glucose and high fatty diets are significantly improved; the Lactobacillus reuteri can be used for preventing, delaying or treating metabolic disorder such as metabolic syndrome, irritable bowel syndrome, and anxiety, depression and other metal diseases related to irritable bowel syndrome.

High cell density cultures of yeast were found to have higher tolerance for butanol in the medium. The high cell density yeast cultures had greater survival and higher glucose utilization than cultures with low cell densities. Production of butanol using yeast in high cell density cultures is thus beneficial for improving butanol production.

The invention discloses a Saccharomyces cerevisiae strain and a method for producing ethanol by fermenting stalks, the strain is Saccharomyces cerevisiae DQ1, the collection No. is CGMCC No.2528, the strain can tolerate methanoic acid, acetic acid and furfural type inhibitors in hydrolyzate of the stalks, tolerate high glucose concentration and ethanol concentration and have wide growth temperature, and the strain is fermented at high temperature; the method for producing the ethanol by fermenting the stalks comprises two-stage culture of seeds, wherein the first stage culture is carried out in a synthetic culture medium for 16-24 hours, the second stage culture is that a mixed culture medium containing 30-70 percent of hydrolyzate is inoculated into with the inoculation amount of 5-10 percent for culture for 15-20 hours, and the inoculation into the hydrolyzate with the inoculation amount of 10 percent or simultaneous saccharification and fermentation of the stalks is further carried out for producing the ethanol. The invention has the advantages of being applicable to high-solid-content stalk enzyme hydrolysis and simultaneous saccharification and fermentation, with short fermentation period, high ethanol yield, and low production cost, thereby having great industrial application prospect.

Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.

A convenient screening tool and a convenient screening method for obtaining an agent for treating diabetes, a pharmaceutical composition for treating diabetes, and a process for manufacturing the pharmaceutical composition are disclosed. The screening tool is a G protein-coupled receptor, a variation functionally equivalent thereto, or a homologous polypeptide thereof which promotes insulin secretion under a high glucose concentration by activation, or cells transformed with an expression vector comprising a polynucleotide encoding the above polypeptide and expressing the polypeptide.

Systems and methods are described providing a hepatic recycling glucose tolerance test for the diagnosis of types and subtypes of diabetes mellitus and other hyperglycemic or hypoglycemic conditions. A method is also provided for screening candidate drugs for treating various types of abnormal glucose metabolism and to monitor whether the course of treatment is effective. The method also allows the correlation of gene activity, hormone and metabolite levels with glucose flux and recycling and an assessment of the degree of hepatic insulin resistance. The method utilizes a preferably non-radioactive stable labeled glucose to asses the relative rates of carbon flow in the liver and provides a hepatic recycling constant that is a measure of the relative rate of glucose recycling. The labeled glucose may be introduced to the patient orally, intravenously or by intraperitoneal administration for the desired effect.

Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided.

The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia.

The invention discloses a brewing yeast strain, which has the classified name Saccharomyces cerevisiae Y09tj, and is preserved in Common Microorganism Center of China General Microbiological Culture Collection Center with the preservation number of CGMCC No.3476. The invention also provides a breeding method for the strain and a method for producing ethanol by quick high-temperature thick mash fermentation of starch. The strain is obtained by the following steps of: separating from common self-brewed sweet wine of peasant families; and performing ultraviolet mutagenesis for breeding. The brewing yeast strain CGMCC NO.3476 has the advantages of quick growth, strong fermentation capacity, high ethanol toxin resistance, and high-glucose concentration resistance of 62 percent (m/v) to the maximum. The average wine yield by the method is improved by 1.2 percent than that of other producing strains, and the wine yield can reach 16.0 percent (v/v); the fermentation period is short, and only 46 hours; the equipment utilization rate can be greatly improved; and the fermentation cost is greatly reduced.

The invention discloses a human adipose-derived stem cell serum-free basic medium. The medium uses a serum substitute, and is composed of a high glucose type DMEM basic medium, human serum albumin, transferrin, taurine, reduced glutathione, ceruloplasmin, L-ascorbic acid-2-sulfate, alpha-tocopherol succinate, linoleic acid, alpha-ketoglutarate and selenium. The serum-free basic medium can exempt potential threats caused by animal serum in conventional serum-containing mediums to human health, and the adipose-derived stem cells cultured by the medium is more suitable for clinical application.

A water soluble extract of M.charantia named MC6, methods for its preparation and methods for its use in the treatment of hyperglycemic disorders are provided. The active MC6 is characterized by moving as a single band on SDS-PAGE having a molecular weight of less than 10 kDal, and by comprising three peptides. Also provided is a peptide component of MC6 named MC6.1, as well as analogues and mimetics thereof. The active MC6, MC 6.1, MC6.2, and MC6.3 exhibit hypoglycemic activity, even following oral administration. Also provided are methods of using the active agents to treat hyperglycemic disorders, particularly diabetes, where the active agents are preferably orally administered.

The invention belongs to a construction method of an animal model, and in particular relates to a construction method of a cynomolgus macaque model for alcoholic liver disease. The construction method of the cynomolgus macaque model for alcoholic liver disease comprises the following steps: screening experimental animals, feeding the screened experimental animals with high-glucose and high-fat feed, and conducting liver biopsy and acquisition of the determined model. The construction method of the cynomolgus macaque model for alcoholic liver disease provided by the invention is short in duration and high in success rate; the construction method is suitable for researching the occurrence mechanism of the alcoholic liver disease and is convenient for screening drugs for treating the alcoholic liver disease and for evaluating the efficacy of the drugs on the alcoholic liver disease; and the construction method has a good application prospect.

The invention discloses a high-sugar and low-protein tilapia feed. Based on the total mass fraction of 100%, it consists of the following components: fish meal: 0-3%, soybean meal: 16-20%, rapeseed meal: 18-21%, cotton meal: 12-16%, secondary meal: 39- 42%, soybean oil: 2-3%, choline chloride: 0.2-0.5%, sodium chloride: 0.1-0.5%, calcium dihydrogen phosphate: 1-2%, vitamin B1: 0.004-0.006%, vitamin B6: 0.002-0.004%, zinc sulfate: 0.02-0.04%, chromium chloride: 0.0001-0.0003%, vitamin premix: 0.1-0.2% and mineral premix: 0.5-1%. The invention maximizes the amount of secondary powder in the feed, adds several plant protein sources to overcome the problem of amino acid imbalance of a single protein source, and at the same time significantly reduces the amount of fish meal. By optimizing and adjusting the feed formula, supplementing suitable vitamin and mineral premixes to adjust the sugar utilization ability of tilapia, so that the tilapia can make good use of the sugar compound of the present invention, avoiding the damage of fish liver caused by high sugar, Fatty liver is formed, and even the fish body becomes obese, and the symptoms of "big belly" appear.

The invention discloses a culture solution for inducing mesenchymal stem cells to differentiate into islet-like cells, and an inducing method and application of the culture solution. The culture solution comprises the following materials: niacinamide, Conophylline, cell growth factor, betacellulin and a base medium. The base medium contains 97% of high glucose DMEM (Dulbecco Modified Eagle Medium), 2% of B-27 and 1% of N-2. The inducing method comprises the following steps of: preparing an inducing culture solution; preparing the human mesenchymal stem cells; taking the human mesenchymal stem cells, inoculating the human mesenchymal stem cells into a six-hole ultralow absorption culture plate by 1.5-2*105cells/hole, adding 3ml inducing culture medium into each hole and carrying out suspended induction; and changing liquid at every 3 days, collecting cell supernatant at the ninth day, and storing the cell supernatant at the temperature of -20 DEG C. The culture solution disclosed by the invention has the advantages that the human mesenchymal stem cells are induced to differentiate into the islet-like cells by utilizing the combination of the niacinamide and the Conophylline, so that the inducing cycle is shortened, the suspension cells are beneficial to being clustered to form cell clusters similar to natural islets, further the induced differentiation efficiency is obviously increased and the clinical application risk is reduced; and the function of inducing the secretion of the cell insulin is obviously improved.